Cinclus Pharma Holding AB (publ) (STO:CINPHA)
Sweden · Delayed Price · Currency is SEK | Market Cap | 602.20M -21.9% |
| Revenue (ttm) | 35.18M -9.0% |
| Net Income | -269.38M |
| EPS | -5.25 |
| Shares Out | 46.54M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 65,423 |
| Open | 12.70 |
| Previous Close | 12.68 |
| Day's Range | 12.70 - 13.04 |
| 52-Week Range | 10.48 - 19.64 |
| Beta | 0.02 |
| Analysts | Strong Buy |
| Price Target | 45.25 (+249.69%) |
| Earnings Date | Nov 11, 2026 |
About Cinclus Pharma Holding AB
Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company’s lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori. Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquar... [Read more]
Full Company ProfileFinancial Performance
In 2025, Cinclus Pharma Holding AB's revenue was 57.47 million, an increase of 1154.80% compared to the previous year's 4.58 million. Losses were -183.97 million, 9.49% more than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for CINPHA stock is "Strong Buy." The 12-month stock price target is kr 45.25, which is an increase of 249.69% from the latest price.
News
Cinclus Pharma Holding AB Transcript: Investing in Life Science 2026
A differentiated drug candidate for severe erosive GERD targets a large unmet need, offering 24-hour acid control and showing superiority over PPIs in trials. Commercialization is advancing in Europe and China, with a pivotal phase III readout expected in Q4, marking a major milestone.
Cinclus Pharma Holding AB Earnings Call Transcript: Q2 2026
Phase III HEEALING1 study for linaprazan glurate completed enrollment, with top-line results expected in Q4 2026. Financials show a SEK 388 million cash balance and high R&D-driven expenses, while the drug's first commercial launch in China marks a key milestone.
Cinclus Pharma Holding AB Quarterly report: Q2 2026
Cinclus Pharma Holding AB has published its Q2 2026 quarterly earnings report on August 19, 2026.
Cinclus Pharma Holding AB Slides: Q2 2026
Cinclus Pharma Holding AB has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 19, 2026.
Cinclus Pharma Holding AB Transcript: Jefferies Global Healthcare Conference 2026
Linaprazan glurate, a next-generation P-CAB for severe erosive GERD, is in phase III trials with top-line results expected in Q4. The drug aims for best-in-class acid control and symptom relief, targeting a large, underserved patient population and potential approval by 2030.
Cinclus Pharma Holding AB Earnings Call Transcript: Q1 2026
Lead asset linaprazan glurate advanced toward pivotal phase III results, with strong regulatory alignment and commercial launches in China. Q1 2026 saw increased R&D spending, improved cash flow, and new financing to support ongoing trials and future growth.
Cinclus Pharma Holding AB Quarterly report: Q1 2026
Cinclus Pharma Holding AB has published its Q1 2026 quarterly earnings report on May 13, 2026.
Cinclus Pharma Holding AB Slides: Q1 2026
Cinclus Pharma Holding AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 13, 2026.
Cinclus Pharma Holding AB Earnings Call Transcript: Q4 2025
Lead candidate linaprazan glurate advances in phase III with strong global partnerships and regulatory progress. Q4 saw increased R&D investment, solid cash reserves, and rising licensing revenues. Market trends and clinical differentiation support significant commercial potential.
Cinclus Pharma Holding AB Quarterly report: Q4 2025
Cinclus Pharma Holding AB has published its Q4 2025 quarterly earnings report on February 18, 2026.
Cinclus Pharma Holding AB Slides: Q4 2025
Cinclus Pharma Holding AB has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 18, 2026.
Cinclus Pharma Holding AB Annual report: Q4 2025
Cinclus Pharma Holding AB has published its Q4 2025 annual report on February 18, 2026.
Cinclus Pharma Holding AB Transcript: KOL Event
Linaprazan glurate, a next-generation PCAB, is positioned to address major unmet needs in severe erosive GERD, offering rapid, superior acid control and targeting a large, dynamic market. Strategic focus on gastroenterologists and strong clinical differentiation are expected to drive adoption.
Cinclus Pharma Holding AB Earnings Call Transcript: Q3 2025
Phase III trial for linaprazan glurate is underway with strong early recruitment and robust financial resources extending into 2027. The product demonstrates superior acid control and healing rates, supporting best-in-class potential as PCABs gain global market share.
Cinclus Pharma Holding AB Quarterly report: Q3 2025
Cinclus Pharma Holding AB has published its Q3 2025 quarterly earnings report on November 20, 2025.
Cinclus Pharma Holding AB Slides: Q3 2025
Cinclus Pharma Holding AB has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 20, 2025.
Cinclus Pharma Holding AB Transcript: Stifel 2025 Healthcare Conference
Linaprazan glurate, a next-generation PCAB, is in Phase III trials targeting severe GERD patients with unmet needs, aiming for premium pricing and specialist market focus. Strong IP, a major European partnership, and a U.S. launch planned for 2029-2030 underpin the strategy.